Brief: Clinuvel Pharmaceuticals Says Afamelanotide Received Positive Opinion For Orphan Drug Designation From EMA
24/06/2024 02:19
June 24 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* DRUG AFAMELANOTIDE RECEIVED POSITIVE OPINION FOR ORPHAN
DRUG
DESIGNATION FROM EUROPEAN MEDICINES AGENCY
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist